Min Zheng

Min Zheng

Auto-generated profile, based on publicly available information

Min Zheng

Department of Cardiology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Key Laboratory of Children’s Important Organ Development and Diseases of Chongqing Municipal Health Commission, National Clinical Key Cardiovascular...

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
YWYingxi Wu
Yingxi Wu
TZTianzhi Zhao
Tianzhi Zhao
YCYaning Cai
Yaning Cai
MZMin Zheng
Min Zheng
YZYunze Zhang
Yunze Zhang
QCqing Cai
qing Cai
OBJECTIVE: The authors aimed to explore the clinical outcomes and risk factors related to recurrence of and survival from solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) that were reclassified according to the 2021 WHO classification of central nervous system (CNS) tumors. METHODS: The authors retrospectively collected and analyzed the clinical and pathological data of SFTs and HPCs recorded from January 2007 to December 2021. Two neuropathologists reassessed pathological slides and regraded specimens on the basis of the 2021 WHO classification. The prognostic factors related to progression-free survival (PFS) and overall survival (OS) were statistically assessed with univariate and multivariate Cox regression analyses. RESULTS: A total of 146 patients (74 men and 72 women, mean ± SD [range] age 46.1 ± 14.3 [3–78] years) were reviewed, and 86, 35, and 25 patients were reclassified as having grade 1, 2, and 3 SFTs on the basis of the 2021 WHO classification, respectively. The median PFS and OS of the patients with WHO grade 1 SFT were 105 months and 199 months after initial diagnosis; for patients with WHO grade 2 SFT, 77 months and 145 months; and for patients with WHO grade 3 SFT, 44 months and 112 months, respectively. Of the entire cohort, 61 patients experienced local recurrence and 31 died, of whom 27 (87.1%) died of SFT and relevant complications. Ten patients had extracranial metastasis. In multivariate Cox regression analysis, subtotal resection (STR) (HR 4.648, 95% CI 2.601–8.304, p < 0.001), tumor located in the parasagittal or parafalx region (HR 2.105, 95% CI 1.099–4.033, p = 0.025), tumor in the vertebrae (HR 3.352, 95% CI 1.228–9.148, p = 0.018), WHO grade 2 SFT (HR 2.579, 95% CI 1.343–4.953, p = 0.004), and WHO grade 3 SFT (HR 5.814, 95% CI 2.887–11.712, p < 0.001) were significantly associated with shortened PFS, whereas STR (HR 3.217, 95% CI 1.435–7.210, p = 0.005) and WHO grade 3 SFT (HR 3.433, 95% CI 1.324–8.901, p = 0.011) were significantly associated with shortened OS. In univariate analyses, patients who received adjuvant radiotherapy (RT) after STR had longer PFS than patients who did not receive RT. CONCLUSIONS: The 2021 WHO classification of CNS tumors better predicted malignancy with different pathological grades, and in particular WHO grade 3 SFT had worse prognosis. Gross-total resection (GTR) can significantly prolong PFS and OS and should serve as the most important treatment method. Adjuvant RT was helpful for patients who underwent STR but not for patients who underwent GTR.

18 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
YYYuan Yuxing
Yuan Yuxing
BPBO PAN
BO PAN
FWFangjie Wang
Fangjie Wang
ZCZhi Chen
Zhi Chen
YGYing Guo
Ying Guo
JTJie Tian
Jie Tian
Background: Although heart failure is a well‐known major global public health concern, the general understanding of the clinical status of pediatric heart failure (PHF) is inadequate. Therefore, this study aims to enhance the general understanding of clinical characteristics across different PHF age groups and provide references for improving PHF treatment strategies. Methods: This multicenter retrospective cohort study involved patients from 20 Chinese provinces, primarily including hospitalized patients (aged ≤18 years) diagnosed with heart failure between January 2013 and December 2022. The study subjects were categorized into 4 groups: neonatal, infant and toddler, young children, and adolescent. Results: Herein, 2903 hospitalized patients with PHF were included. Significant differences were observed across age groups in clinical characteristics, auxiliary examination results, comorbid diagnoses, and hospitalization outcomes. After adjusting for covariates, the odds of in‐hospital death were significantly lower in the infant and toddler (odds ratio [OR], 0.46 [95% CI, 0.25–0.85]), young children (OR, 0.39 [95% CI, 0.18–0.85]), and adolescent (OR, 0.34 [95% CI, 0.13–0.87]) groups compared with the neonatal group. Furthermore, the odds of cardiovascular adverse events were significantly higher in the young children (OR, 1.91 [95% CI, 1.62–2.88]) and adolescent (OR, 2.16 [95% CI, 1.15–4.06]) groups compared with the neonatal group. Additionally, regarding the odds of a bad Ross class, the adolescent group had 1.85 times higher odds (95% CI, 1.11–3.09) compared with the neonatal group, 2.36 times (95% CI, 1.67–3.35) higher odds compared with the infant and toddler group, and 1.45 times (95% CI, 1.05–2.02) higher odds compared with the young children group ( P <0.05). Conclusions: This study emphasizes the importance of age‐specific stratification in PHF management, revealing distinct clinical and prognostic differences across various developmental stages. Registration: URL: https://www.chictr.org.cn . Unique identifier: ChiCTR2300078262.

1 September 2023 in Materials Express
Verified
Journal Article
Closed access
XQXinger Qian
Xinger Qian
XDXiaowei Dai
Xiaowei Dai
QYQiuhong Yang
Qiuhong Yang
JYJing Ying
Jing Ying
MZMin Zheng
Min Zheng
Dexmedetomidine affects the activity of lymphocytes behind the head, but the molecular mechanism is unclear. 40 SPF SD rats were separated into control group, dexmedetomidine group, pathway inhibitor group, and positive control group, followed by analysis of CD4+, CD4+/CD8+, CD8+ T cell ratios, T lymphocyte proliferation inhibition rate, expression of T lymphocyte metabolism-related genes such as β-ACTIN, HIF1A, GLUT1, HK2 and JAK2/STAT3 signaling pathway factors such as p-JAK2, p-STAT3, JAK2, STAT3. The ratios of CD4+ and CD4+/CD8+ T cells in dexmedetomidine group and positive control group were higher and that of CD8+ T cells was lower, which all showed opposite changes in pathway inhibitor group. Cell proliferation inhibition rates in dexmedetomidine and positive control group were markedly lower and those of control group and pathway inhibitor group were both higher. The expression of β-ACTIN, HIF1A, GLUT1 and HK2 related to T lymphocyte metabolism were the lowest in dexmedetomidine group and positive control group (P < 0.05), while control group and the pathway inhibitor group were higher (P < 0.05). The expression of p-JAK2 and p-STAT3 were the highest in dexmedetomidine group (P < 0.05). Dexmedetomidine nanocrystals can inhibit the expression of T lymphocyte metabolism-related genes such as β-ACTIN, HIF1A, GLUT1, and HK2, thereby down-regulating CD4+/CD8+ cells, inhibiting proliferation and metabolism of lymphocytes behind the head and ears, and maintaining the number and function of T lymphocytes. The molecular mechanism of dexmedetomidine is related to the JAK2/STAT3 pathway, which can be used as a target for dexmedetomidine nanocrystals to improve the proliferation and metabolism of lymphocytes.